Meeting
2018 Gastrointestinal Cancers Symposium
Folfirinox (FFX) versus gemcitabine with nab‐paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience.
Authors
Ivan Barrera
Jewish General Hospital, McGill University, Montreal, QC, Canada
Ivan Barrera , Sabina Hamalova , Jill Ranger , Henry Rho , Aline Mamo , Gerald Batist , Petr Kavan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 414)
DOI
10.1200/JCO.2018.36.4_suppl.414
Abstract #
414
Poster Bd #
K7
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano
Poster
2020 Gastrointestinal Cancers Symposium
Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System.
First Author: Timil Patel
Poster
2020 Gastrointestinal Cancers Symposium
Real-world patterns of care among patients with metastatic pancreatic cancer (mPC).
First Author: Eileen Mary O'Reilly
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang